Cerecin (formerly known as CereSpir) is a clinical-stage pharmaceutical company developing novel therapeutics for Alzheimer's disease and other central nervous system disorders. The company's lead compound, AZD-0328, targets the cholinergic system to improve cognitive function.
Cerecin was founded in 2014 as a spinout from the University of Sydney, initially operating under the name CereSpir. The company was established to commercialize research from the university's Brain and Mind Centre, which had been conducting pioneering work on cholinergic signaling and nicotinic acetylcholine receptors.
In 2019, Cerecin relocated its headquarters from Sydney, Australia to Cambridge, Massachusetts, aligning with the company's strategic goal of accessing the deeper biotech ecosystem and investor base in the United States. This move positioned Cerecin among the world's leading biotechnology clusters and facilitated stronger partnerships with major pharmaceutical companies[1].
The company's name change from CereSpir to Cerecin reflected its evolution from a research-focused startup to a clinically-oriented biopharmaceutical company with broader ambitions in CNS drug development.
Cerecin's lead compound is a novel positive allosteric modulator (PAM) of the alpha-7 nicotinic acetylcholine receptor (α7 nAChR). This receptor plays a critical role in cognitive function, attention, and memory, and is a validated target for Alzheimer's disease therapeutics[1:1].
AZD-0328 has undergone extensive preclinical and clinical evaluation:
Cerecin continues to explore additional compounds targeting neurodegenerative diseases through modulation of nicotinic acetylcholine receptors and other cognitive pathways[2]. The company's pipeline includes:
The alpha-7 nicotinic acetylcholine receptor is a ligand-gated ion channel abundant in brain regions involved in cognition, including the hippocampus and prefrontal cortex. In Alzheimer's disease, α7 nAChR function is often impaired, contributing to cognitive deficits[3].
Benefits of positive allosteric modulation:
The cholinergic system plays a crucial role in memory and attention. In Alzheimer's disease, there is progressive loss of cholinergic neurons in the basal forebrain, leading to decreased acetylcholine levels in key brain regions. This cholinergic deficit is a hallmark of AD and underlies many of the cognitive symptoms experienced by patients.
Cerecin's approach targets this deficit directly by enhancing signaling through the α7 nAChR, which may help compensate for lost cholinergic input and improve cognitive function in AD patients.
Cerecin has established several strategic partnerships to advance its pipeline:
Cerecin operates in the competitive Alzheimer's disease therapeutic space, competing with:
Cerecin differentiates itself through its novel mechanism of action targeting α7 nAChR, which may offer advantages over existing cholinesterase inhibitors.
Cerecin company history and background. Retrieved 2026-03-22. 2026. ↩︎ ↩︎
Cerecin pipeline and programs. 2026. ↩︎
Alpha-7 nicotinic acetylcholine receptor in Alzheimer's disease. 2026. ↩︎